Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Cardiotoxicity is a severe side effect of drugs that induce structural or electrophysiological changes in heart muscle cells. As a result, the heart undergoes failure and potentially lethal arrhythmias. It is still a major reason for drug failure in preclinical and clinical phases of drug discovery. Current methods for predicting cardiotoxicity are based on guidelines that combine electrophysiological analysis of cell lines expressing ion channels ectopically in vitro with animal models and clinical trials. Although no new cases of drugs linked to lethal arrhythmias have been reported since the introduction of these guidelines in 2005, their limited predictive power likely means that potentially valuable drugs may not reach clinical practice. Human pluripotent stem cell‐derived cardiomyocytes (hPSC‐CMs) are now emerging as potentially more predictive alternatives, particularly for the early phases of preclinical research. However, these cells are phenotypically immature and culture and assay methods not standardized, which could be a hurdle to the development of predictive computational models and their implementation into the drug discovery pipeline, in contrast to the ambitions of the comprehensive pro‐arrhythmia in vitro assay (CiPA) initiative. Here, we review present and future preclinical cardiotoxicity screening and suggest possible hPSC‐CM‐based strategies that may help to move the field forward. Coordinated efforts by basic scientists, companies and hPSC banks to standardize experimental conditions for generating reliable and reproducible safety indices will be helpful not only for cardiotoxicity prediction but also for precision medicine. Linked Articles: This article is part of a themed section on New Insights into Cardiotoxicity Caused by Chemotherapeutic Agents. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.21/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
WITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
RetractedA New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 2×
“We anticipate that the integration of hiPSC-CMs in early, preclinical stages of drug development is imminent and will be of benefit in: (i) the early detection of cardiotoxic drugs in safety pharmacology assays, which will help reduce the withdrawal of drugs already introduced to the market; (ii) the refinement of dru…”
BackgroundCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153 · cited 1×
“This could be provided by recent advances in genome-editing techniques, with CRISPR/Cas9 being the current leading method (Sander and Joung, 2014).”
BackgroundClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 2×
“Cardiotoxicity caused by electrical disruption A second form of cardiotoxicity, commonly evident in the early phases of drug discovery, is the acute and direct, detrimental effect of drugs on the electrophysiological properties of CMs (Cook et al., 2014).”
BackgroundO'Hara, T., Virág, L., Varró, A., & Rudy, Y. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002061 · Cited by 1,196 · cited 1×
“Computational models for ion currents are being generated based on existing electrophysiological data measured in adult animal/human CMs as well as hPSC-CMs and then integrated into complex single- or multi-cellular models (O'Hara et al., 2011; Paci et al., 2013).”
MethodModelling the long QT syndrome with induced pluripotent stem cells
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., et al. (2011) · Nature · doi:10.1038/nature09747 · Cited by 1,049
Multi-electrode array technologies for neuroscience and cardiology
Spira, M. E., & Hai, A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.265 · Cited by 991
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Tissue Engineering of a Differentiated Cardiac Muscle Construct
Zimmermann, W.-H., Schneiderbanger, K., Schubert, P., Didié, M., Münzel, F., Heubach, J. F., Kostin, S., Neuhuber, W. L., & Eschenhagen, T. (2002) · Circulation Research · doi:10.1161/hh0202.103644 · Cited by 917
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407 · cited 1×
“The resulting contractile and electrical dysfunction often leads to abnormal heartbeat and life-threatening arrhythmias (Ewer and Ewer, 2015; Gintant et al., 2016).”
BackgroundMatsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr073 · Cited by 389
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293 · cited 2×
“Phenotypic variability High line-to-line variability (although only modest clonal variability in cells from one line) is still a widespread problem that requires joint efforts to solve, although recent, robust, methodologies have contributed to mitigating the issues (Burridge et al., 2011; Hartjes et al., 2014; Dennin…”
BackgroundPaull, D., Sevilla, A., Zhou, H., Hahn, A. K., Kim, H., Napolitano, C., Tsankov, A., Shang, L., Krumholz, K., Jagadeesan, P., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3507 · Cited by 263 · cited 1×
“Fully automated, high-throughput procedures to reprogramme hiPSC from somatic cells have been developed (Paull et al., 2015) with the aim of limiting variability.”
BackgroundKyttälä, A., Moraghebi, R., Valensisi, C., Kettunen, J., Andrus, C., Pasumarthy, K. K., Nakanishi, M., Nishimura, K., Ohtaka, M., Weltner, J., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.12.009 · Cited by 257 · cited 2×
“In a study on four isogenic lines from healthy donors (Kyttälä et al., 2016), up to 158 genes were found to be differently expressed among the lines; some were imprinted, evidence for a role of epigenetic memory in determining the phenotype and differentiation potential of hPSC, possibly by…”
BackgroundControlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture
Feinberg, A. W., Alford, P. W., Jin, H., Ripplinger, C. M., Werdich, A. A., Sheehy, S. P., Grosberg, A., & Parker, K. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.043 · Cited by 240 · cited 2×
“, 2015a), although it has been demonstrated that substrate stiffness plays a major role in the quantification of absolute force values (Feinberg et al., 2012; Ribeiro et al., 2015b).”
BackgroundRibeiro, M. C., Tertoolen, L. G., Guadix, J. A., Bellin, M., Kosmidis, G., D'Aniello, C., Monshouwer-Kloots, J., Goumans, M.-J., Wang, Y.-L., Feinberg, A. W., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.067 · Cited by 214
Self-citationInduced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Human engineered heart tissue as a model system for drug testing
Eder, A., Vollert, I., Hansen, A., & Eschenhagen, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.010 · Cited by 190 · cited 3×
“…stimuli, such as adjusted pacing frequency (Chan et al., 2013), 3D-microenvironments (Zhao et al., 1999; Nunes et al., 2013; Hirt et al., 2014; Eder et al., 2016) and heterotypic cell co-culture (Robertson et al., 2013) may all contribute to cell maturation, increasing the expression of ion…”
BackgroundA small, physiological electric field orients cell division
Zhao, M., Forrester, J. V., & McCaig, C. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4942 · Cited by 186
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium
Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-228007 · Cited by 184 · cited 2×
“, 2015), engineered heart tissues (Zimmermann and Schneiderbanger, 2002; Turnbull et al., 2014) or 3D vascularized cardiac layers (Mosadegh et al.”
BackgroundStudying cardiac arrhythmias in the mouse—a reasonable model for probing mechanisms?
Nerbonne, J. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2003.12.006 · Cited by 175
Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes
Mehta, A., Sequiera, G. L., Ramachandra, C. J. A., Sudibyo, Y., Chung, Y., Sheng, J., Wong, K. Y., Tan, T. H., Wong, P., Liew, R., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu060 · Cited by 110
Cited by
Giacomelli, E., Meraviglia, V., Campostrini, G., Cochrane, A., Cao, X., van Helden, R. W. J., Krotenberg Garcia, A., Mircea, M., Kostidis, S., Davis, R. P., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.05.004 · Cited by 622
Self-citationSala, L., van Meer, B. J., Tertoolen, L. G. J., Bakkers, J., Bellin, M., Davis, R. P., Denning, C., Dieben, M. A. E., Eschenhagen, T., Giacomelli, E., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312067 · Cited by 416
“relevance where comparisons of contraction data across multiple platforms are required by regulatory agencies or consortia (eg, CiPA [Comprehensive In Vitro Proarrhythmia Assay] and CSAHi [Consortium for Safety Assessment Using Human iPS Cells]).(5,6,25,30) Moreover, this might offer a quantitative approach to investi…”
Self-citationBlinova, K., Dang, Q., Millard, D., Smith, G., Pierson, J., Guo, L., Brock, M., Lu, H. R., Kraushaar, U., Zeng, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.079 · Cited by 373
Molecular and functional variation in iPSC-derived sensory neurons
HIPSCI Consortium, Schwartzentruber, J., Foskolou, S., Kilpinen, H., Rodrigues, J., Alasoo, K., Knights, A. J., Patel, M., Goncalves, A., Ferreira, R., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0005-8 · Cited by 223
Inspiration from heart development: Biomimetic development of functional human cardiac organoids
Richards, D. J., Coyle, R. C., Tan, Y., Jia, J., Wong, K., Toomer, K., Menick, D. R., & Mei, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.021 · Cited by 166
“Despite immature characteristics of cardiac organoids compared to adult ventricular tissue, the presence of fundamental physiological cardiac functions provided a basis for exploring critical pathways involved in cardiac pathologies, supported by recent progress using hiPSC-CMs for cardiac pathophysiology insights (12…”
Background
Metadata
- Authors
- Sala, L., Bellin, M., & Mummery, C. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-09-20
- Volume
- 174
- Issue
- 21
- Pages
- 3749-3765
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2523625328
- Cited by
- 121
- References
- 30
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.